ReviewFrontiers in pediatrics2026
Interleukin-6 in complications of prematurity: from biomarker to targeted therapy.
Review in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prematurity is a major cause of neonatal morbidity and mortality. Inflammatory imbalance is critical in preterm complications, and interleukin-6 (IL-6) plays a pivotal role in this dysregulation. Currently, there is no comprehensive review focusing specifically on IL-6 in the context of neonatal complications of prematurity. Thus, we review the involvement of IL-6 in various prematurity complications, exploring its mechanisms and clinical implications. We also discuss current and emerging therapies targeting IL-6, its receptor, and the trans-signaling pathway, focusing on the potential of these cytokines as therapeutic targets for the development of safe and effective treatments for neonatal complications of prematurity. However, while IL-6 shows consistent value as an early predictive biomarker, its translation into targeted therapy for preterm infants remains preliminary, with substantial gaps in safety and pharmacokinetic data that require further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.